SARTORIUS STEDIM BIOTECH - SDMHF STOCK NEWS

Sartorius Stedim Biotech reported a 22.1% increase in sales revenue for H1 2022, reaching approximately 1,724 million euros, driven by organic growth and acquisitions. The underlying EBITDA margin stood at 35.2%. The company confirmed its 2022 outlook, expecting sales growth of 15-19% and a stable EBITDA margin. However, it noted increased uncertainties due to geopolitical tensions and economic instability. Despite a slight decline in order intake compared to H1 2021, the group remains confident due to healthy demand in the biopharma sector.

Sartorius reported a strong start to fiscal 2022, with sales revenue increasing by 25.4% in constant currencies to approximately 1,025 million euros. Underlying EBITDA surged by 32.4%, reaching 349 million euros, and the EBITDA margin improved to 34.1%. Despite the growth, order intake fell 5.8% due to exceptionally high demand in the prior year. The company confirmed its 2022 outlook, expecting sales revenue growth of 15% to 19% and a stable EBITDA margin of around 34%. However, geopolitical uncertainties have increased, raising risks for supply chains.

Sartorius Stedim Biotech reported a strong start to 2022, achieving 27.6% sales revenue growth in constant currencies, reaching approximately 862 million euros. The underlying EBITDA margin remained robust at 35.2%, with net profit rising 34.4% to 203 million euros. The company confirmed its 2022 outlook, predicting revenue growth between 15% and 19%. However, rising global uncertainties, particularly due to the Ukraine crisis, may impact supply chains and inflation rates.

Sartorius Stedim Biotech S.A. announced a dividend of 1.26 euros per share for fiscal 2021 during its Annual General Shareholders' Meeting held on March 29, 2022. The total distributed profit amounts to 116.1 million euros, significantly increasing from 0.68 euros in the previous year. Shareholders also renewed appointments for directors, including Pascale Boissel and Joachim Kreuzburg, for three years. The company continues its growth trajectory, with a reported sales revenue of approximately 2.89 billion euros in 2021, employing over 10,400 people.

Sartorius Stedim Biotech presented its Universal Registration Document 2021 on February 17, 2022, confirming previously disclosed preliminary figures for fiscal 2021. The company forecasts a 15% to 19% increase in Group sales revenue for fiscal 2022, with a 35% EBITDA margin. Key figures from 2021 include €2.89 billion in sales revenue, a 70.9% increase in EBITDA, and an underlying net profit of €687.8 million. The company emphasizes its commitment to innovation and sustainability in the biopharma industry.

The Board of Directors of Sartorius Stedim Biotech has proposed a dividend of 1.26 euros per share for fiscal 2021, marking an increase from 0.68 euros per share the previous year. This proposal will be presented at the Annual General Shareholders' Meeting on March 29, 2022, with a total distributed profit of €116.1 million. The board also plans to renew the terms of five directors. Notably, Sartorius earned approximately €2.89 billion in sales revenue in 2021 and has seen consistent annual growth.

Sartorius Stedim Biotech has completed the acquisition of Novasep's chromatography division as of February 7, 2022. This acquisition, initially agreed in early 2021, is expected to add approximately 1 percentage point in non-organic sales revenue growth, raising the company's overall forecast for 2022 to a 15-19 percent increase. The business acquired generated 40 million euros in sales in 2020. Sartorius remains committed to strong profitability, with an underlying EBITDA margin expected to exceed 35 percent for the year.

Sartorius Stedim Biotech reported remarkable fiscal 2021 growth, achieving a 52.6% increase in sales revenue to €2.887 billion, driven largely by strong demand in biopharmaceutical manufacturing and the pandemic's impact. Order intake surged by 55.6% to €3.664 billion, with pandemic-related demand contributing significantly. Earnings before interest, taxes, depreciation, and amortization (EBITDA) rose 70.9% to €1.033 billion, pushing the EBITDA margin to 35.8%. The company aims for double-digit growth in 2022 and has set ambitious CO2 emission reduction targets.

Sartorius Stedim Biotech reported impressive growth for the nine months ending September 30, 2021, with sales revenue soaring by 56.2% to approximately 2,109 million euros. This growth stemmed from robust demand in biopharmaceutical manufacturing and a 24 percentage points contribution from coronavirus vaccine production. Order intake rose by 78.4% to 2,852 million euros, highlighting strong market activity. Underlying EBITDA increased 76.1% to 766 million euros, while net profit surged 83.0% to 509 million euros. The company remains optimistic and confirmed its full-year forecast.